ARCT
Price
$12.38
Change
-$0.26 (-2.06%)
Updated
Jun 13 closing price
Capitalization
335.75M
57 days until earnings call
LCTX
Price
$0.81
Change
+$0.11 (+15.71%)
Updated
Jun 13 closing price
Capitalization
185.08M
53 days until earnings call
Interact to see
Advertisement

ARCT vs LCTX

Header iconARCT vs LCTX Comparison
Open Charts ARCT vs LCTXBanner chart's image
Arcturus Therapeutics Holdings
Price$12.38
Change-$0.26 (-2.06%)
Volume$433.1K
Capitalization335.75M
Lineage Cell Therapeutics
Price$0.81
Change+$0.11 (+15.71%)
Volume$4.78M
Capitalization185.08M
ARCT vs LCTX Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. LCTX commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and LCTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (ARCT: $12.38 vs. LCTX: $0.81)
Brand notoriety: ARCT and LCTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 101% vs. LCTX: 376%
Market capitalization -- ARCT: $335.75M vs. LCTX: $185.08M
ARCT [@Biotechnology] is valued at $335.75M. LCTX’s [@Biotechnology] market capitalization is $185.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileLCTX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • LCTX’s FA Score: 0 green, 5 red.
According to our system of comparison, LCTX is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while LCTX’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • LCTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LCTX is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -3.21% price change this week, while LCTX (@Biotechnology) price change was +20.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

LCTX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($336M) has a higher market cap than LCTX($185M). LCTX YTD gains are higher at: 61.294 vs. ARCT (-27.048). LCTX has higher annual earnings (EBITDA): -20.87M vs. ARCT (-77.4M). ARCT has more cash in the bank: 237M vs. LCTX (47.8M). LCTX has less debt than ARCT: LCTX (2.51M) vs ARCT (28.6M). ARCT has higher revenues than LCTX: ARCT (138M) vs LCTX (9.5M).
ARCTLCTXARCT / LCTX
Capitalization336M185M182%
EBITDA-77.4M-20.87M371%
Gain YTD-27.04861.294-44%
P/E RatioN/AN/A-
Revenue138M9.5M1,453%
Total Cash237M47.8M496%
Total Debt28.6M2.51M1,138%
FUNDAMENTALS RATINGS
ARCT vs LCTX: Fundamental Ratings
ARCT
LCTX
OUTLOOK RATING
1..100
2946
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9292
PRICE GROWTH RATING
1..100
6335
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LCTX's Valuation (43) in the null industry is in the same range as ARCT (47) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew similarly to ARCT’s over the last 12 months.

LCTX's Profit vs Risk Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew similarly to ARCT’s over the last 12 months.

LCTX's SMR Rating (92) in the null industry is in the same range as ARCT (92) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew similarly to ARCT’s over the last 12 months.

LCTX's Price Growth Rating (35) in the null industry is in the same range as ARCT (63) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew similarly to ARCT’s over the last 12 months.

LCTX's P/E Growth Rating (62) in the null industry is somewhat better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew somewhat faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTLCTX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMUAX14.57-0.09
-0.61%
Federated Hermes Muni and Stock Adv A
MGKIX13.85-0.12
-0.86%
Morgan Stanley Global Permanence I
JDVAX15.98-0.14
-0.87%
JPMorgan Diversified A
CGEOX18.66-0.18
-0.96%
Calamos Global Equity R6
OLVRX20.27-0.22
-1.07%
JPMorgan Large Cap Value R4

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
+15.37%
MDGL - LCTX
43%
Loosely correlated
-0.55%
ABCL - LCTX
35%
Loosely correlated
+1.59%
ATOS - LCTX
35%
Loosely correlated
-3.74%
ARCT - LCTX
35%
Loosely correlated
-2.06%
ATAI - LCTX
34%
Loosely correlated
-3.21%
More